Shire plc: Results of the Annual General Meeting Held on April 28, 2009
Posted on: Tuesday, 28 April 2009, 10:34 CDT
** A vote "withheld" is not a vote in law and is not counted in the calculation of the votes "for" or "against" a resolution.
Two copies of all resolutions passed, other than resolutions concerning
ordinary business, will shortly be submitted to the UK Listing Authority and
will be available for inspection at the UK Listing Authority's Document
Viewing Facility, which is situated at the Financial Services Authority, 25
The North Colonnade, Canary Wharf,
Notes to Editors
SHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: http://www.shire.com.
For further information please contact: Shire plc: Tony Guthrie, Deputy Company Secretary, +44(0)1256-894746 Investor Relations Clea Rosenfeld (Rest of the World) +44-1256-894-160 Eric Rojas (North America) +1-617-551-9715 Media Jessica Mann (Rest of the World) +44-1256-894-280 Matthew Cabrey (North America) +1-484-595-8248 Jessica Cotrone (North America) +1-617-613-4640SOURCE Shire Plc
Source: PR Newswire
Related Articles
- Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
- Shire plc: Core Portfolio of Products Delivers 20% Sales Growth
- Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
- Publication of Shire plc's Annual Report 2008
- Shire plc: Change to Director's Details
- Amicus Therapeutics and Shire Plc Enter Into $440 Million Ex-US Licensing Agreement to Develop and Commercialize Amigal(TM), Plicera(TM) and At2220
- Shire Plc (SHPGY) Chief Executive Officer and Chief Financial Officer to Ring the NASDAQ Stock Market Opening Bell
- Shire Plc Signs Marketing Agreement With Samaritan Pharma; Samaritan to Commercialize Shire's ELAPRASE to Treat Hunter's Disease in Greece and Cyprus
- Shire Plc - Statement Regarding the United States Food and Drug Administration Drug Safety and Risk Management Advisory Committee Meeting
 |
 |
User Comments (0)
RSS Feeds